Le semorinemab est un anticorps monoclonal thérapeutique, développé par AC Immune et Genentech. Il cible la protéine Tau, supposée responsable de la maladie d'Alzheimer.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| prop-fr:c |
|
| prop-fr:drugbank |
|
| prop-fr:h |
|
| prop-fr:n |
|
| prop-fr:nom |
|
| prop-fr:o |
|
| prop-fr:s |
|
| prop-fr:wikiPageUsesTemplate | |
| dct:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| rdfs:seeAlso | |
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| foaf:name |
|
| is dbo:wikiPageWikiLink of | |
| is oa:hasTarget of | |
| is foaf:primaryTopic of |
